高德美将展示ARTIST上市后研究的结果，表明Shayping Technique™——一种使用三种瑞蓝®透明质酸钠凝胶注射产品的整体治疗方案能显著改善面部特征和整体外观，支持其满足不同求美者需求的应用¹。
其他报告将重点介绍高德美美学产品组合的多样性，如何满足求美者和医生不断变化的需求，包括应对药物驱动减重后的面部美学变化、再生美学以及肉毒毒素领域的进展²-⁵。
公司还将在高德美展位通过专题研讨会、医学事务会议以及多场“专家面对面”和实验室互动环节，提供美学领域最广泛产品组合的最新动态。
10月1日至3日，致力于成为全球领先的专业皮肤学公司瑞士高德美，将在阿联酋迪拜举行的全球抗衰老美容医学大会（AMWC）上，展示六份海报，分享其基于科学的美学产品组合的最新成果。公司还将在多个活动中展示其在美学教育领域的领导力，包括专题研讨会、医学事务会议，并将在其展位B-145举办由专家社区合作伙伴主导的“专家面对面”和互动实验室课程。
“我们在AMWC迪拜的亮相，体现了高德美致力于成为美学领域真正合作伙伴的承诺——拥有全球最广泛的注射美学产品组合、规模化商业布局以及领先的培训活动与服务。通过此类活动，我们可以直接与从业者互动，密切了解他们不断变化的需求。这些经验，结合我们的科学创新，有助于赋能从业者，实现真正符合求美者需求的美学效果。”
FLEMMING ØRNSKOV
医学博士，公共卫生硕士
高德美
首席执行官
瑞蓝在个性化美学中的优势得到进一步验证
高德美将展示来自ARTIST海外研究的上市后数据，该研究针对其瑞蓝透明质酸（HA）注射剂产品组合，该组合独特的配方旨在与皮肤自身的HA紧密匹配和协同作用，呈现自然的效果¹,⁶,⁷。海外数据支持了该系列最新创新产品——采用全新NASHA HD™技术的瑞蓝·Shaype™——单独用于下巴区域，或与瑞蓝·丽瑅丽多®联合用于中面部治疗，和/或与瑞蓝·定采®联合用于下巴的柔和过渡时，效果显著¹。
在所有组别中，研究者和求美者均一致认为，100%的求美者在注射后第4周和第8周时，面部美学改善明显，且根据全球美学改善量表（GAIS ，Global Aesthetic Improvement Scale）评估¹。结果满意度也在所有组别中保持较高，100%的患者报告在第8周时，下巴轮廓得到改善，效果自然¹。此外，研究者发现，瑞蓝Shaype在所有患者中注射后位置稳定，并且注射部位可以立即按摩和塑形，以实现理想效果¹。此外，还将展示新见解，强调酶体积与填充剂体积的比例，对实现有效且可预测的填充剂溶解效果起着关键作用⁸。
推动高德美在再生美容领域的创新，以及应对药物驱动的体重下降带来的面部美学影响
高德美将分享关于塑妍萃®的专家共识海外研究结果，进一步加强其对各层皮肤作用的理解³,⁹-¹³。经过海外研究表明，PLLA-SCA™的作用包括激活成纤维细胞，刺激胶原蛋白、弹性蛋白及其他参与细胞外基质再生的蛋白质³。#这些效果在临床上可表现为皮肤特性的长期改善、体积恢复和紧致度提升、皮肤质量和厚度增加等益处³。#专家小组基于收集的分子科学数据和文献，得出结论：PLLA-SCA™有望在再生美学领域发挥关键作用³。#
高德美还将展示关于塑妍萃®与瑞蓝·丽瑅®·丽多TM或Contour™*的三个月联合治疗的海外数据，以解决因药物驱动减重而出现面部容积流失的美学问题²。专家面部整形外科医生Michael Somenek博士将于10月1日（星期三）上午11点（GST时间）/ 上午9点（CEST时间）在Al Ameera宴会厅3号厅进行演讲。该海外研究结果显示，塑妍萃®与瑞蓝·丽瑅®·丽多TM或Contour联合治疗方案不仅改善了容积，还提升了皮肤质量；#其中，瑞蓝·丽瑅®·丽多TM显著改善了皮肤水合度，而塑妍萃®则显著改善了皮肤光泽度和厚度²。#
为应对这一日益增长的患者需求，高德美将于10月2日（星期四）上午11点至下午1点（GST时间）/ 上午9点至11点（CEST时间），在Baniyas宴会厅1号厅举办题为“药物驱动的体重下降带来的美学变化”的专题研讨会。美学专家Mohamed Alsufyani博士、Shadan Naji博士、Firas Hamdan博士、Daniel Coimbra博士、Alessandra Haddad博士和Michael Somenek博士将探讨药物驱动的体重下降对面部的影响，并展示应对这些变化的美学方法，包括现场演示。这是高德美支持行业需求，识别并解决经历药物驱动体重下降的患者面临的主要美学问题的努力的一部分，相关内容已在高德美近期的报告中概述。
“处方减重药物的使用呈指数增长，这促使医美界迅速调整，以理解由此带来的相关美学需求。因此，在AMWC迪拜上设立这样一个平台至关重要，分享关于如何解决这些求美者独特美学需求的最新见解显得尤为重要，例如展示塑妍萃®和瑞蓝®如何协同作用，改善面部美学效果，更提升患者的情绪健康。”
MICHAEL SOMENEK
医学博士
面部整形外科医生
美国华盛顿特区
数据凸显求美者对液态肉毒毒素创新成果的高满意度
高德美将在会议上展示来自READY临床试验计划的四项研究结果，这些研究评估了新型液态A型肉毒毒素**——首款也是唯一一款采用PEARL™技术的即用型液态肉毒毒素⁴,¹⁴。这项创新更为便捷，无需复溶，简化了临床工作流程并确保剂量稳定¹⁵。
当用于治疗眉间纹和鱼尾纹时，联合结果证实其最快可在第1天起效，并且效果可持续长达6个月⁴。受试者也报告了持续的高满意度，突显了新型液态A型肉毒毒素重新定义求美者对肉毒毒素期望的潜力⁴。
说明：
*在美国以外的国家和地区，瑞蓝Contour™被称为瑞蓝·丰采®
**新型液态肉毒毒素产品还未获批在中国大陆市场上市
#塑妍萃®等不同产品的实际使用，应严格遵守国家药监局核准的相关产品中文说明书。
关于瑞蓝产品组合
瑞蓝透明质酸（HA）注射剂的设计不同于常规注射剂，超越单纯的容积填充，旨在实现自然的效果¹⁶-¹⁹。我们的HA纯度极高，与皮肤的HA高度接近²⁰。创新的制造工艺保持了其生物相容性，同时制造出专门针对特定需求的个性化产品。瑞蓝独特的技术，如NASHA HD、NASHA®和OBT™技术，旨在模仿面部结构和皮肤层的多样性¹⁶-¹⁸。凭借优异的支撑性和拉伸力，瑞蓝可提供结构支撑、自然表情和健康光泽¹⁷,²⁰-²⁴。近三十年来备受信赖，瑞蓝的HA凝胶与皮肤协同作用，呈现100%自然效果¹⁶,²⁵,²⁶。
关于塑妍萃®
塑妍萃®是首款经过验证的聚左旋乳酸填充剂。独特的聚左旋乳酸（PLLA-SCA™）配方，能够作用于皮肤的三层结构⁹-¹³,²⁷，快速、渐进、持续地实现效果。塑妍萃®的效果持久，治疗一个月后即可显现效果，且海外数据显示，可持续两年以上⁹,³⁰-³⁷。
关于新型液态A型肉毒毒素
由高德美首创的Relfydess是首款也是唯一一款采用PEARL技术的即用型液态肉毒毒素，旨在保持分子完整性¹⁴。PEARL技术旨在提供一种高活性、创新的无复合物分子，最多39%的患者在第1天即可见效，最多75%的患者可维持六个月的改善效果¹⁴,³⁸,³⁹。新型液态A型肉毒毒素经过优化，可实现简单的体积剂量给药，无需复溶，提高易用性并有助于确保每次剂量/体积的稳定性¹⁵,⁴⁰。它完全由高德美研发和生产，作为市场上最广泛的注射美学产品组合的一部分，扩展了其肉毒毒素产品线。新型液态A型肉毒毒素已在多个市场获得上市许可。
关于高德美
高德美（瑞士证券交易所：股票代码为“GALD”）致力于成为专注皮肤学领域的全球领导者，业务遍及约90个国家和地区。我们提供创新、以科学为基础的优质旗舰品牌和服务组合，横跨注射美学、日常护肤和皮肤治疗这三个快速增长的皮肤学细分市场。自1981年成立以来，我们一直热忱专注于人体最大的器官——皮肤，与专业医务工作者合作，以卓越成果满足求美者、消费者和患者的个性化需求。肌肤塑造了我们的人生故事，由此，我们致力于不断推进“每一个进步 为每一寸肌肤”。
参考资料
1.Nikolis A, et al. The ARTIST post-marketing study: Evaluating a high G’ hyaluronic acid injectable for chin treatment in combination with other hyaluronic acid fillers for lower face and midface treatment. Poster #11675 presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC); October 1-3, 2025; Dubai, United Arab Emirates.
2.Somenek M, et al. Synergistic efficacy and safety of poly-L-lactic acid biostimulator and hyaluronic acid filler for facial fullness post-weight loss due to Glucagon-Like Peptide-1 receptor agonist medication. Poster #11706 presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC); October 1-3, 2025; Dubai, United Arab Emirates.
3.Fabi S, et al. Regenerative aesthetic effects of poly L-lactic acid treatment. Poster #11707 presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC); October 1-3, 2025; Dubai, United Arab Emirates.
4.Donofrio L, et al. Efficacy and safety results from four Phase III studies on liquid relabotulinumtoxinA for treatment of glabellar lines and/or lateral canthal lines. Poster #11694 presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC); October 1-3, 2025; Dubai, United Arab Emirates.
5.Schlessinger J, et al. High subject satisfaction with abobotulinumtoxinA treatment of glabellar lines post-marketing across the globe. Poster #11680 presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC); October 1-3, 2025; Dubai, United Arab Emirates.
6.Edsman K, et al. Gel properties of HA dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
7.Verpaele A and Strand A. Restylane SUBQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. Aesthetic Surg J. 2006;26(Suppl.):S10–17. doi: 10.1016/j.asj.2005.09.009.
8.Nikolis A, Prygova I, and Bromée T. Hyaluronidase applications in aesthetics: Clinical evidence and the call for consensus-based guidelines. Poster #11676 presented at the Aesthetic & Anti-Aging Medicine World Congress (AMWC); October 1-3, 2025; Dubai, United Arab Emirates.
9.Sculptra. U.S. Instructions for use. Available online. Accessed September 2025.
10.Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6. 2024; Paris, France.
11.Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.
12.Zubair R, et al. SPLASH: Split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg. 2024;50(12):1155-1162. doi: 10.1097/DSS.0000000000004417.
13.Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042.
14.Shridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. Aesthet Surg J. 2024; 44(12):1330-1340. doi: 10.1093/asj/sjae131.
15.Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.
16.Di Gregorio C. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
17.Nikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12. doi: 10.1093/asjof/ojaa005.
18.Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
19.Restylane. U.S. Instructions for use. Available online. Accessed September 2025.
20.Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
21.Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco.
22.Narins RS, et al. Persistence of nasolabial fold correction with a HA dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37: 644-650. doi: 10.1111/j.1524-4725.2010.01863.x.
23.Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18-month open multicenter study. Dermatol Surg. 2015;41: 1361–1369. doi: 10.1097/DSS.0000000000000549.
24.Ohrlund A, et al. Differentiation of NASHA and OBT HA gels according to strength, flexibility, and associated clinical significance. J Drugs Derm. 2024; 23(1): 1332-1336. doi: 10.36849/JDD.7648.
25.Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3): 738-746. doi: 10.1111/jocd.12961.
26.Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7): 1600-1606. doi: 10.1111/jocd.13205.
27.Fabi S, et al. Effectiveness and safety of correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant - clinical study data up to 24 months. Poster presented at IMCAS World Congress; January 26-28, 2023; Paris, France.
28.Zhang S and Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755.
29.Shuster S, Black MM, and McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-643. doi: 10.1111/j.1365-2133.1975.tb05113.x.
30.Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–922. doi: 10.1111/dsu.12164.
31.Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48: 101–108. doi: 10.1097/DSS.0000000000003239.
32.Waibel J, et al. Gene analysis of biostimulators: PLLA-SCA triggers regenerative morphogenesis while CaHa-R induces inflammation upon facial injection. Poster presented at ASDS 2024; October 17-20, 2024; Florida, United States.
33.Waibel J, et al. Bulk RNA-Seq analysis of PLLA-SCA vs CaHa-R reveals a novel, adipocyte mediated regenerative mechanism of action unique to PLLA. Poster presented at ASDS 2024; October 17-20, 2024; Florida, United States.
34.Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229.
35.Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.
36.Hexsel D, Hexsel CL, and Cotofana S. Introducing the L-Lift: A Novel Approach To Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122-1124. doi: 10.1097/DSS.0000000000002015.
37.Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC; March 30 - April 1, 2023; Monaco.
38.Ablon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. Toxicon. 2024; 237(1): 107353. doi: 10.1026/j.toxicon.2024.107353.
39.Relfydess®. EU Summary of Product Characteristics.
40.Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.
